GLYC グリコミメティス
- 0.3200
- -0.0100-3.03%
- 0.3267
- +0.0067+2.09%
グリコミメティスのニュース一覧
グリコミメティス | 10-Q：Q3 2024 四半期報告書
Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024
GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting
M&A Deals Roundup: AbbVie, Blackstone, Take-Two Interactive and More
GlycoMimetics Announces Merger With Crescent Biopharma
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
GlycoMimetics GLYC Crescent Merger; Coya COYA Phase 2 Data
Top Midday Gainers
GlycoMimetics Shares Are Soaring Tuesday: Here's Why
Shareholder Alert: Ademi LLP Investigates Whether GlycoMimetics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Correction to GlycoMimetics Acquisition Article
GlycoMimetics GLYC Acquisition Deal; Shuttle Pharmaceuticals SHPH Phase 2 Trial Plans
GlycoMimetics Shares Are Trading Higher After the Company Announced It Will Merge With Crescent Biopharma and Secured $200 in Funding to Advance Its Oncology Pipeline.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Trading Halt: Halt Status Updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times
GlycoMimetics Agrees to Be Taken Private by Crescent Biopharma
GlycoMimetics: Combined Co Will Advance Crescent's Portfolio of Precision-Engineered Biologics to Improve Outcomes for Patients With Solid Tumors >GLYC
Glycomimetics Shares Fall After Leukemia Treatment Trial Misses Key Goal
Trading Halt: Halted at 6:55:00 A.m. ET - Trading Halt: Halt News Pending
GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint
分析
今後の予想（目標株価）
データなし
データなし